Journal
SCIENTIFIC REPORTS
Volume 12, Issue 1, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41598-022-16455-1
Keywords
-
Categories
Funding
- Swedish Childhood Cancer Foundation [SF-NBCNSPDHEL10/021, NCp2015-0061, TJ2014-0064, TM-2016-147, 2017-166, PK-2017-0122]
- Swedish Cancer Foundation [TM-18-1711, PK-19-0566]
- Nilsson-Ehle Foundation [HK-29211]
- Swedish state under the LUA/ALF [ALFGBG-447171]
- Laboratory Division of Sahlgrenska University Hospital
- Assar Gabrielssons Foundation
- Sahlgrenska University Hospital Foundation
- Swedish Research Council [TM/SF-2014-3031]
- Swedish Foundation for Strategic Research [TM/PK-RB13-0204]
- EC [826494]
- Vienna Science and Technology Fund WWTF [LS18-111]
- St. Anna Kinderkrebsforschung
- Lions Cancer Fund West
Ask authors/readers for more resources
In neuroblastoma, amplification of 12q loci, particularly CDK4 and MDM2, is common and can be targeted for inhibition to reduce cell proliferation, especially in p53(wild-type) cells. The combination of CDK4/MDM2 inhibition has an additive effect in p53(wild-type) cell lines but not p53(mutated) cells. This aggressive neuroblastoma subgroup with 12q amplification and atypical clinical presentation may benefit from CDK4 and/or MDM2 inhibition according to in vitro studies.
In neuroblastoma, MYCN amplification and 11q-deletion are important, although incomplete, markers of high-risk disease. It is therefore relevant to characterize additional alterations that can function as prognostic and/or predictive markers. Using SNP-microarrays, a group of neuroblastoma patients showing amplification of one or multiple 12q loci was identified. Two loci containing CDK4 and MDM2 were commonly co-amplified, although amplification of either locus in the absence of the other was observed. Pharmacological inhibition of CDK4/6 with ribociclib or abemaciclib decreased proliferation in a broad set of neuroblastoma cell lines, including CDK4/MDM2-amplified, whereas MDM2 inhibition by Nutlin-3a was only effective in p53(wild-type) cells. Combined CDK4/MDM2 targeting had an additive effect in p53(wild-type) cell lines, while no or negative additive effect was observed in p53(mutated) cells. Most 12q-amplified primary tumors were of abdominal origin, including those of intrarenal origin initially suspected of being Wilms' tumor. An atypical metastatic pattern was also observed with low degree of bone marrow involvement, favoring other sites such as the lungs. Here we present detailed biological data of an aggressive neuroblastoma subgroup hallmarked by 12q amplification and atypical clinical presentation for which our in vitro studies indicate that CDK4 and/or MDM2 inhibition also could be beneficial.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available